Date: 2014-02-24
Type of information: Private placement
Company: BioInvent (Sweden)
Investors:
Amount: MSEK 64 (€ 7.16 million)
Funding type:
Planned used: The issue proceeds will be used to strengthen BioInvent’s financial position and to ensure the Company’s capital requirements during the coming 12-18 months.
Others: * On February 24, 2014, BioInvent has announced that its Board of Directors has resolved on a rights issue of approx. MSEK 49 (€ 5.8 million) and a directed new share issue of approx. MSEK 15 (€1.68 million). The new share issues are subject to approval by an Extraordinary General Meeting on 19 March 2014. The final terms of the new share issues will be announced on 18 March 2014 at the latest. The rights issue is secured by subscription undertakings and guarantee undertakings of up to approx. 75 percent of the issue, including subscription undertakings from the two largest shareholders O.G.B.B. A. van Herk B.V. and B&E Participation AB
The right to subscribe for shares in the directed issue will be granted a limited number of investors of institutional character and the issue price will be the same as in the rights issue. The Company has received soft commitments regarding subscription for the shares in the directed issue. The record date for entitlement to participate in the rights issue is 24 March 2014. The subscription period in the rights issue runs from and including 28 March until and including 11 April 2014.
Therapeutic area: Cancer - Oncology
